Concord Biotech possessed six fermentation-based immunosuppressant APIs as of March 31, 2022, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus. It had a total annual installed fermentation capacity of 1,250 m3 cubic meters for APIs. It has two DSIR (Department of Science and Industrial Research)-approved R&D divisions with a total of 163 people. The company has three manufacturing facilities in Gujarat, India, including API manufacturing facilities in Dholka and Limbasi, as well as a formulation manufacturing facility in Valthera.
Open Date: August 4, 2023
Grey Market Premium: ₹325
Expected Return: 44%
Concord Biotech IPO is an India-based biopharma company that is one of the world’s leading developers and manufacturers of select fermentation-based APIs in immune suppressants and oncology, supplying 200 customers in over 70 countries, including regulated sectors such as the United States, Europe, and Japan, as well as India.
Concord Biotech IPO Details
| IPO Open: | August 4, 2023 |
| IPO Close: | August 8, 2023 |
| IPO Size: | Approx ₹1551 Crores |
| Offer for Sale: | Approx 20,925,652 Equity Shares |
| Face Value: | ₹1 Per Equity Share |
| IPO Price Band: | ₹705 to ₹741 Per Share |
| IPO Listing on: | BSE & NSE |
| Retail Quota: | 35% |
| QIB Quota: | 50% |
| NII Quota: | 15% |
| Discount: | N/A |
Concord Biotech Financial Performance
| FY 2021 | FY 2022 | FY 2023 | |
|---|---|---|---|
| Revenue | 616.94 | 712.93 | 853.17 |
| Expenses | 317.58 | 495.19 | 568.42 |
| Net income | 234.89 | 174.93 | 240.08 |
| Margin (%) | 38.07 | 24.54 | 28.14 |
Concord Biotech Valuations & Margins
| FY 2021 | FY 2022 | FY 2023 | |
|---|---|---|---|
| EPS | 22.45 | 16.72 | 22.95 |
| PE ratio | – | – | 30.72 – 32.29 |
| RONW (%) | 26.55 | 16.64 | 20.06 |
| NAV | 95.53 | 105.45 | 123.31 |
| ROCE (%) | 28.54 | 20.55 | 24.27 |
| EBITDA (%) | 53.02 | 37.82 | 40.47 |
| Debt/Equity | 0.09 | 0.05 | 0.02 |
Concord Biotech IPO Subscription – Live Updates
- Coming soon
Concord Biotech IPO Dates & Listing Performance
| Concord Biotech IPO Opening Date | 4 August 2023 |
| Concord Biotech IPO Closing Date | 8 August 2023 |
| Finalization of Basis of Allotment | 11 August 2023 |
| Initiation of refunds | 14 August 2023 |
| Transfer of shares to demat accounts | 17 August 2023 |
| Concord Biotech IPO Listing Date | 18 August 2023 |
| Opening Price on NSE | ₹ 900 |
| Closing Price on NSE | ₹ 943 |
Concord Biotech IPO GMP FAQs
What is the current GMP for Concord Biotech?
The current GMP for the Concord Biotech IPO is ₹180.
When will the Concord Biotech IPO open?
The IPO for Concord Biotech opens on August 4, 2023 and closes on August 8, 2023.
What is Concord Biotech IPO Expected Returns?
Concord Biotech IPO Expected Returns is 24%.
What is the Concord Biotech IPO lot size?
Concord Biotech’s IPO lot size is 20 shares, and the minimum amount required is ₹14,820.
Concord Biotech Offer Lead Manager
KOTAK MAHINDRA CAPITAL COMPANY LIMITED
27BKC, 1st Floor, Plot no. C-27,
‘G’ Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051
Phone: +91 22 4336 0000
Email: cbl.ipo@kotak.com
Website: https://www.investmentbank.kotak.com
Concord Biotech Offer Registrar
LINK INTIME INDIA PRIVATE LIMITED
C-101, 1st Floor, 247 Park, L.B.S. Marg,
Vikhroli (West), Mumbai – 400083, Maharashtra
Phone: +91 22 49186200
E-mail: concordbiotech.ipo@linkintime.co.in
Website: https://www.linkintime.co.in
Concord Biotech Contact Details
CONCORD BIOTECH LIMITED
16th floor, B-Wing, Mondeal Heights,
Iscon Cross Road, S.G. Highway, Ahmedabad – 380015
Phone: 079-6813 8700
Email: complianceofficer@concordbiotech.com
Website: https://www.concordbiotech.com
Concord Biotech Offer News
- Concord Biotech RHP
- Concord Biotech DRHP
- ASBA IPO Forms
- Live IPO Subscription Status
- IPO Subscription Status
